EUVIMEDEUVIMED entdecken
Crossref

Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019–2023

Samuel R Bunting iD, Robert O Cotes iD, Kathryn Gray, Kristen Chalmers, Thuy D Nguyen

Psychiatric Services · 2025

DOI: 10.1176/appi.ps.20230593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychiatric Services, 2025. Verfasst von Samuel R Bunting und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Neuroscience (Bunting, Gray), Department of Pharmacy (Gray), and Pritzker School of Medicine (Chalmers), Univ…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Medicare Part D, Prior Authorization, Formularies as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Long-acting injectable antipsychotics (LAIAPs) enable safe and effective long-term management of chronic psychotic disorders but are underused in clinical practice. The authors examined whether Medicare formulary restrictions (prior authorization [PA] or step therapy) impose barriers to LAIAP uptake. METHODS: The authors analyzed formulary restrictions and patient cost-sharing for several LAIAPs and estimated the percentage of plans (N=2,494 were available per year) applying formulary restrictions. Analyses were stratified by Medicare Advantage, dual Medicare-Medicaid eligibility plans, and Part D plan group and weighted by the number of enrollees at the per-year, per-plan level. RESULTS: Application of formulary restrictions for LAIAPs was low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsMedicare Part DPrior AuthorizationFormularies as TopicMedicare Part CMedicareHumansUnited StatesDelayed-Action PreparationsMedicaidInjectionsCost Sharing

Stichwörter der Autor:innen

Formulary restrictionLong-acting injectable antipsychoticMedicaidMedicare Part DPrior authorizationPsychosis treatment

Substanzen

Antipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Neuroscience (Bunting, Gray), Department of Pharmacy (Gray), and Pritzker School of Medicine (Chalmers), University of Chicago, Chicago; Department of Psychiatry and Behavioral Sc…

ORCID-Profile: Samuel R Bunting, Robert O Cotes

Zitieren

APA

Bunting, S. R., Cotes, R. O., Gray, K., Chalmers, K., & Nguyen, T. D. (2025). Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019–2023. Psychiatric Services. https://doi.org/10.1176/appi.ps.20230593

Vancouver

Bunting SR, Cotes RO, Gray K, Chalmers K, Nguyen TD. Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019–2023. Psychiatric Services. 2025. doi:10.1176/appi.ps.20230593

BibTeX
@article{Bunting2025,
  author = {Bunting, Samuel R and Cotes, Robert O and Gray, Kathryn and Chalmers, Kristen and Nguyen, Thuy D},
  title = {Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019–2023},
  journal = {Psychiatric Services},
  year = {2025},
  doi = {10.1176/appi.ps.20230593}
}
Kostenlos starten →